Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib vs Bevacizumab in metastatic colorectal cancer
NCT00384176Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2006
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of cediranib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Progression Free Survival. Started Aug 2006; status: completed.
02
Drugs
cediranib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00384176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384176.